A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Cutaneous Sarcoidosis

Interventions

DRUG

Oral Brepocitinib

Drug: Oral Brepocitinib

DRUG

Oral Placebo

Drug: Oral Placebo

Trial Locations (4)

RECRUITING

Clinical Trial Site, Philadelphia

RECRUITING

Clinical Trial Site, Durham

RECRUITING

Clinical Trial Site, Madison

RECRUITING

Clinical Trial Site, San Francisco